Abstract: The invention relates to the pharmaceutical or non-pharmaceutical use of an effective amount of spirulina and/or of an extract/extracts of spirulina for improving the bioavailability of orally administered curcumin in humans or animals. The invention also includes pharmaceutical or non-pharmaceutical preparations including spirulina and/or extracts of spirulina containing curcumin having improved bioavailability.

Abstract: Provided is a method for improving the yield of rhamnolipids comprising culturing in medium containing a triglyceride containing oil and sweetener as a carbon source.

Abstract: Embodiments of the invention relate generally to processes for the production and processing of polyhydroxyalkanoates (PHA) from carbon sources. In several embodiments, PHAs are produced at high efficiencies from carbon-containing gases through the utilization of a regenerative polymerization system.

Abstract: The present invention relates to the field of culturing unicellular red algae (URA). The invention relates in particular to a method for culturing URA, characterised in that the culture medium includes milk permeate as the main contribution of at least one carbon source. The invention also relates to biomass which can be obtained by the method according to the invention, to the uses of said biomass and to the products that can include said biomass.

Abstract: The present invention relates to an additive to poultry feed including nitrates, nitrites or their mixtures that reduces the incidence of pectoral myopathy in poultry, for example, wooden breast myopathy in broiler chickens. In one aspect, a method for reducing the incidence of pectoral myopathy in poultry is disclosed. The method includes feeding poultry a feed having one or more nitrates, one or more nitrites, or a mixture thereof, wherein the amount of nitrates and/or nitrites in the feed is 3 g to 2,500 g per ton of feed.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one Corynebacterium sp, Staphylococcus pasteuri and, optionally, Staphyloccocus epidermidis for use as a medicament, in particular for use in the prevention or treatment of S. aureus colonization.

Abstract: The invention relates to a process for the conversion of lignocellulose into an organic acid including an alkaline pretreatment step and a fermentation step, wherein liquid phase obtained in the fermentation step is recycled to the alkaline pretreatment step and/or the fermentation step. Organic acid is recovered as its magnesium of calcium salt from solid phase obtained in the fermentation step.

Abstract: The present disclosure provides methods for generating sugars from a cellulosic biomass. The methods combine treatment of the biomass using a high-shear milling device and saccharification of the biomass to partially hydrolyze the biomass. The biomass can be saccharified either after or simultaneously with the high-shear milling treatment. The partially hydrolyzed biomass is then separated into a solids stream with saccharification enzymes, and a liquid stream with sugars. The solids stream and associated enzymes are further incubated under saccharification conditions to produce additional sugars, or are recycled and added to fresh biomass, which is saccharified under high-shear milling conditions. The methods result in improved conversion of cellulosic biomass to glucose.

Abstract: A method for manufacturing bacterially induced crystal particle includes culturing bacteria in a culture medium including a carbon source and a raw metal material including a transition metal, so that the bacteria induce a raw metal material to undergo a reduction-oxidation reaction; isolating a wet powder material from the culture medium; and drying the wet powder material to obtain a powder material. The powder material includes at least one bacterially induced crystal particle.

Abstract: Human-derived probiotic strains Lactobacillus paracasei KBL382, Lactobacillus paracasei KBL384 and Lactobacillus paracasei KBL385 are described, as well as uses of the strains for improving intestinal health and treating or preventing intestinal diseases. The strains have excellent anti-inflammatory and immunomodulatory functions, superb strengthening effects on tight junctions of the intestinal tract wall, suppress enteritis-induced weight loss and colon length reduction, thereby exhibiting therapeutic effects for enteritis, and significantly alleviate the symptoms of atopic dermatitis. The strains can be used as probiotic material for enhancing anti-inflammatory effects, strengthening immunity, improving intestinal health functions, and alleviating allergic diseases.

Abstract: Methods for diagnosing, treating, and monitoring the treatment of fusariosis or scedosporiosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having fusariosis or scedosporiosis.

Abstract: The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

Abstract: A method of controlling a bioreactor system includes providing a cell culture in a bioreactor, wherein conditions in the bioreactor enable the cell culture to produce a protein of interest (POI), measuring process parameters (PPs) of the culture within the bioreactor by RAMAN, wherein the process parameters are selected from the group consisting of nutrient concentration, viable cell concentration, and protein attributes, measuring a predetermined weight of the bioreactor with the cell culture, removing cell-free spent media from the cell culture using a first output conduit at a first specified rate, removing cells from the cell culture using a second output conduit at a second specified rate, and introducing one or both of fresh media or nutrients into the cell culture using an input conduit at a third specified rate.

Abstract: A device and method for analyte detection and analytes in a particulate bearing fluid such as whole blood having an instrument for partitioning the particles from the fluid that is integrated with a detector for analyzes of one or more particulate bearing fluid analytes while the particles in the particulate bearing fluid are partitioned.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A Bifidobacterium lactis BL-99 strain capable of enhancing immunity and the use thereof, which belongs to the technical field of microorganisms, is described. The Bifidobacterium lactis BL-99 provided by the present invention is deposited in China General Microbiological Culture Collection Center CGMCC on Apr. 26, 2018 with the deposit number CGMCC No. 15650. The bacteria have gastric acid resistance and intestinal fluid resistance, can significantly promote the growth of Bifidobacterium and Lactobacillus, significantly increase antibody-producing cells and half hemolysis value HC50, activate NK cell activity, and can be used to prepare foods for immunity enhancement. It also has the effects in preventing osteoporosis, increasing blood calcium and/or phosphorus ions, which has a wide range of application prospects.

Abstract: A composition for treating irritable bowel syndrome can include a mixture of Bacillus amyloliquefaciens, Enterococcus faecium, and Vitamin D (Calciferol). The composition can be administered to a patient to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome. For example, the composition can be used to treat colitis. The composition can include about 1×106 to 1×1012 colony forming units (CFU) of Bacillus amyloliquefaciens and Enterococcus faecium per unit dose. In an embodiment, the composition can include at least 1 to 25 mg/L Vitamin-D.

Abstract: The present invention relates to a feed supplement for addition to drinking water, for improved animal health. The feed supplement includes short chain fatty acids, a nitrogenous compound, a source of inositol and a source of xylanase. The feed supplement reduces the need for pharmaceutical inputs and increases both animal health and yield.

Abstract: A composition for treating irritable bowel syndrome can include a mixture of Bacillus amyloliquefaciens, Enterococcus faecium, and Vitamin D (Calciferol). The composition can be administered to a patient to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome. For example, the composition can be used to treat colitis. The composition can include about 1×106 to 1×1012 colony forming units (CFU) of Bacillus amyloliquefaciens and Enterococcus faecium per unit dose. In an embodiment, the composition can include at least 1 to 25 mg/L Vitamin-D.

Abstract: A method of inhibiting oral pathogens comprising administering to a subject in need thereof an effective amount of Lactobacillus strain-containing food composite, medical composite and oral cleaning composite. The food composite, medical composite and oral cleaning composite comprises at least one Lactobacillus strain, which is at least one isolated Lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain, CCTCC NO: M2011124; Lactobacillus salivarius subsp. salicinius AP-32 strain, CCTCC NO: M2011127; Lactobacillus reuteri GL-104 strain, CCTCC NO: M209138; Lactobacillus paracasei GL-156 strain, CCTCC NO: M2014590; Lactobacillus helveticus RE-78 strain, CGMCC No. 13513; Lactobacillus rhamnosus CT-53 strain, CCTCC NO: M2011129; and Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).